Ocugen Announces Positive Preliminary Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
Ocugen Announces Positive Preliminary Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration GlobeNewswire January 15, 2026 Phase 2 (~50% of patients evaluated to date at 12 months) shows 46% lesion growth reduction vs. control There are no OCU410-related serious adverse events reported across the Phase 1 […]